{
    "clinical_study": {
        "@rank": "53821", 
        "arm_group": [
            {
                "arm_group_label": "GT1:NC MK-5172/MK-8742+SOF 4wk", 
                "arm_group_type": "Experimental", 
                "description": "MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 4 weeks (n=30)"
            }, 
            {
                "arm_group_label": "GT1:NC MK-5172/MK-8742+SOF 6wk", 
                "arm_group_type": "Experimental", 
                "description": "MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 6 weeks (n=30)"
            }, 
            {
                "arm_group_label": "GT1:C MK-5172/MK-8742+SOF 6wk", 
                "arm_group_type": "Experimental", 
                "description": "MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 6 weeks (n=20)"
            }, 
            {
                "arm_group_label": "GT1:C MK-5172/MK-8742+SOF 8wk", 
                "arm_group_type": "Experimental", 
                "description": "MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 8 weeks (n=20)"
            }, 
            {
                "arm_group_label": "GT3:NC MK-5172/MK-8742+SOF 8wk", 
                "arm_group_type": "Experimental", 
                "description": "MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 8 weeks (n=15)"
            }, 
            {
                "arm_group_label": "GT3:NC MK-5172/MK-8742+SOF 12wk", 
                "arm_group_type": "Experimental", 
                "description": "MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 12 weeks (n=15)"
            }, 
            {
                "arm_group_label": "GT3:C MK-5172/MK-8742+SOF 12wk", 
                "arm_group_type": "Experimental", 
                "description": "MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 12 weeks (n=10)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study of MK-5172A and sofosbuvir (SOF) in treatment-naive participants with\n      chronic hepatitis C (HCV) genotype 1 (GT1) or genotype 3 (GT3). The objective is to\n      determine the proportion of subjects achieving sustained virologic response (SVR) 12 weeks\n      (SVR12) after ending study treatment."
        }, 
        "brief_title": "Efficacy and Safety of MK-5172, MK-8742, and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is an open-label, single-center, multiple-arm investigation of MK-5172A (a fixed\n      dose combination [FDC] of MK-5172 [100mg] and MK-8742 [50mg]), and SOF 400mg, in\n      treatment-naive participants with chronic HCV GT1 or GT3. The impact of study treatment\n      regimens of varying duration on SVR12 (defined as HCV ribonucleic acid [RNA] that is lower\n      than the limit of quantitation at 12 weeks after the end of study treatment) in cirrhotic\n      (C) and non-cirrhotic (NC) participants infected with HCV GT1 or GT3 will be determined"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HCV RNA \u226510,000 IU/mL in peripheral blood at the time of screening\n\n          -  documented chronic HCV GT1 or GT3 infection\n\n          -  negative or positive history of liver cirrhosis based on liver biopsy, Fibroscan, or\n             FibroSure \u00ae (Fibrotest\u00ae)\n\n          -  treatment na\u00efve to all anti-HCV treatment\n\n        Exclusion Criteria:\n\n          -  has evidence of decompensated liver disease\n\n          -  is coinfected with hepatitis B virus (e.g. hepatitis B surface antigen positive) or\n             human immunodeficiency virus\n\n          -  history of malignancy \u22645 years prior to signing informed consent, or is under\n             evaluation for other active or suspected malignancy\n\n          -  has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of\n             hepatocellular carcinoma (HCC) or is under evaluation for HCC\n\n          -  has clinically-relevant drug or alcohol abuse within 12 months of screening\n\n          -  has any of the following conditions: organ transplants other than cornea and hair,\n             poor venous access that precludes routine peripheral blood sampling, history of\n             gastric surgery or malabsorption disorders, or any medical condition requiring, or\n             likely to require, chronic systemic administration of corticosteroids during the\n             course of the trial\n\n          -  history of chronic hepatitis not caused by HCV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133131", 
            "org_study_id": "5172-074"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "GT1:NC MK-5172/MK-8742+SOF 4wk", 
                    "GT1:NC MK-5172/MK-8742+SOF 6wk", 
                    "GT1:C MK-5172/MK-8742+SOF 6wk", 
                    "GT1:C MK-5172/MK-8742+SOF 8wk", 
                    "GT3:NC MK-5172/MK-8742+SOF 8wk", 
                    "GT3:NC MK-5172/MK-8742+SOF 12wk", 
                    "GT3:C MK-5172/MK-8742+SOF 12wk"
                ], 
                "description": "FDC tablet (100mg MK-5172/50mg MK-8742), oral once daily (QD)", 
                "intervention_name": "MK-5172/MK-8742 FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "GT1:NC MK-5172/MK-8742+SOF 4wk", 
                    "GT1:NC MK-5172/MK-8742+SOF 6wk", 
                    "GT1:C MK-5172/MK-8742+SOF 6wk", 
                    "GT1:C MK-5172/MK-8742+SOF 8wk", 
                    "GT3:NC MK-5172/MK-8742+SOF 8wk", 
                    "GT3:NC MK-5172/MK-8742+SOF 12wk", 
                    "GT3:C MK-5172/MK-8742+SOF 12wk"
                ], 
                "description": "Sofosbuvir 400mg tablet, oral QD", 
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 6, 2014", 
        "number_of_arms": "7", 
        "official_title": "A Phase II Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172, MK-8742, and Sofosbuvir in Treatment-Na\u00efve Subjects With Chronic HCV GT1 and GT3 Infection", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of participants achieving SVR12", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "measure": "Number of participants experiencing at least 1 adverse event (AE) on study", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 36"
            }, 
            {
                "measure": "Number of participants discontinuing study therapy due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133131"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of participants achieving SVR4", 
            "safety_issue": "No", 
            "time_frame": "Up to 16 weeks"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}